JinkoSolar And Solar's Dramatic Expansion

Keith Williams profile picture
Keith Williams
8.38K Followers

Summary

  • 65% of JKS solar PV sales in 2022 were in China (up 3-fold) & Europe (doubling year-over-year). This makes the company less dependent on US business.
  • Jinko’s top solar panels (N-type TOPCon) are expected to have 25.8% efficiency when mass produced by end of 2023. This is a big deal.
  • Notwithstanding problems in the US in recent years, JKS sales in the US are expected to increase in 2023.
  • JKS produced 44.6 GW of solar panels in 2022 and expects to produce 60-70 GW of solar panels in 2023. JKS is also expanding its battery (ESS) business.
  • In light of massive growth in solar PV just about everywhere (and JKS is just about everywhere), a revaluation of JKS' share price is surely close.

Businessman draws increase arrow graph corporate future growth year 2022 to 2023. Planning,opportunity, challenge and business strategy. New Goals, Plans and Visions for Next Year 2023.

Galeanu Mihai

I'm an investor who looks to get ahead of big changes that will impact the investment scene. While my background is in the biotech industry, I think that the massive change that we are experiencing is the electrification

1year share prices

1year comparison JKS, CSIQ, FSLR (Seeking Alpha)

This article was written by

Keith Williams profile picture
8.38K Followers
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science. Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity. Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering. With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.

Disclosure: I/we have a beneficial long position in the shares of JKS, CSIQ, FSLR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (7)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.